Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Equillium, Inc. (EQ) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Notice of Delisting or Failure to...
Docs: "OPEN MARKET SALE AGREEMENT SM",
"Equillium, Inc."
10/05/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "Equillium Reports Second Quarter 2023 Financial Results and Provides Corporate and Clinical Updates $48.4 million in cash at the end of Q2 2023 expected to provide operating runway into 2025 Fully prepaid and retired debt facility Authorized $7.5 million stock repurchase program"
05/25/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
05/23/2023 4 Xu Yu (Katherine) (Director) has filed a Form 4 on Equillium, Inc.
Txns: Granted 20,000 options to buy @ $0.65, valued at $13k
05/23/2023 4 Troupin Barbara (Director) has filed a Form 4 on Equillium, Inc.
Txns: Granted 20,000 options to buy @ $0.65, valued at $13k
05/23/2023 4 Pruzanski Mark (Director) has filed a Form 4 on Equillium, Inc.
Txns: Granted 20,000 options to buy @ $0.65, valued at $13k
05/23/2023 4 McDermott Charles Douglas (Director) has filed a Form 4 on Equillium, Inc.
Txns: Granted 20,000 options to buy @ $0.65, valued at $13k
05/23/2023 4 MANIAN BALA S (Director) has filed a Form 4 on Equillium, Inc.
Txns: Granted 20,000 options to buy @ $0.65, valued at $13k
05/23/2023 4 DEMSKI MARTHA J (Director) has filed a Form 4 on Equillium, Inc.
Txns: Granted 20,000 options to buy @ $0.65, valued at $13k
05/23/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Equillium Reports First Quarter 2023 Financial Results and Provides Clinical Updates $62.0 million cash balance at the end of Q1 2023 expected to provide operating runway into 2025 Presented Phase 1b EQUATE data in aGVHD highlighting rapid and durable rates of overall clinical response, clinical response associated with improved progression-free survival through one year, and steroid tapering of 99% at Day 169&#x200b"
04/13/2023 ARS Form ARS - Annual Report to Security Holders:
04/13/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/06/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
03/31/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
03/23/2023 10-K Annual Report for the period ended December 31, 2022
03/23/2023 8-K Quarterly results
Docs: "Equillium Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate & Clinical Development Updates"
03/03/2023 SC 13G/A VICTORY CAPITAL MANAGEMENT INC reports a 3.9% stake in Equillium, Inc.
02/07/2023 4 BRADBURY DANIEL (Executive Chairman) has filed a Form 4 on Equillium, Inc.
Txns: Granted 38,000 options to buy @ $3.59, valued at $136.4k
02/07/2023 4 Connelly Stephen (Chief Scientific Officer) has filed a Form 4 on Equillium, Inc.
Txns: Granted 125,000 options to buy @ $3.86, valued at $482.5k
02/07/2023 4 Keyes Jason A (CFO) has filed a Form 4 on Equillium, Inc.
Txns: Granted 125,000 options to buy @ $3.86, valued at $482.5k
02/07/2023 4 Rothman Joel (Chief Development Officer) has filed a Form 4 on Equillium, Inc.
Txns: Granted 125,000 options to buy @ $3.86, valued at $482.5k
02/07/2023 4 Steel Bruce D. (President and CEO) has filed a Form 4 on Equillium, Inc.
Txns: Granted 325,000 options to buy @ $3.86, valued at $1.3M
02/07/2023 4 Zedelmayer Christine (Sr. Vice President and COO) has filed a Form 4 on Equillium, Inc.
Txns: Granted 125,000 options to buy @ $3.86, valued at $482.5k
01/31/2023 SC 13G/A VICTORY CAPITAL MANAGEMENT INC reports a 12.2% stake in Equillium, Inc.
01/06/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
01/06/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
01/04/2023 4 BRADBURY DANIEL (Executive Chairman) has filed a Form 4 on Equillium, Inc.
Txns: Granted 50,000 options to buy @ $1.06, valued at $53k
01/04/2023 4 Connelly Stephen (Chief Scientific Officer) has filed a Form 4 on Equillium, Inc.
Txns: Granted 175,000 options to buy @ $1.06, valued at $185.5k
01/04/2023 4 Keyes Jason A (CFO) has filed a Form 4 on Equillium, Inc.
Txns: Granted 4,444 shares @ $1.19, valued at $5.3k
Granted 175,000 options to buy @ $1.06, valued at $185.5k
01/04/2023 4 Rothman Joel (Chief Development Officer) has filed a Form 4 on Equillium, Inc.
Txns: Granted 6,244 shares @ $1.85, valued at $11.6k
Granted 3,821 shares @ $1.19, valued at $4.5k
Granted 175,000 options to buy @ $1.06, valued at $185.5k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy